小児臨床試験市場-世界の産業規模、シェア、動向、機会、予測、2018～2028年：フェーズ別、試験設計別、治療領域別、地域別、競合

世界の小児臨床試験市場は、2022年に147億米ドルと評価され、2028年までのCAGRは7.50%で、予測期間中に目覚ましい成長を遂げると予測されています。

小児臨床試験とは、乳幼児、小児、青少年を含む小児集団における治療、介入、薬剤、機器、療法の安全性、有効性、投与量を評価するために実施される調査です。これらの臨床試験は、小児が罹患する疾患や病状の理解と治療を改善するために不可欠です。小児臨床試験の実施には、インフォームド・コンセントを含む倫理原則を重視する必要があります。両親または法定後見人が、小児の参加者に代わってインフォームド・コンセントを行います。研究者は、小児にとって臨床試験の利益が潜在的なリスクを上回ることを確認しなければならないです。小児臨床試験では、治療の効果を評価するために特定のエンドポイントやアウトカムを測定します。これには、症状の改善、疾患の進行、QOL、安全性プロファイルなどが含まれます。

希少疾患や慢性疾患を含む小児疾患の有病率は増加傾向にあります。このため、小児に有効な治療法を開発するための臨床試験の必要性が高まっています。ゲノミクスと分子生物学の進歩により、小児疾患に対する標的療法が開発されています。これらの革新的な治療法には、安全性と有効性を評価するための臨床試験が必要です。小児科の臨床試験の多くは、従来の医薬品開発では十分な治療が受けられないことが多い希少疾患を対象としています。希少疾病用医薬品のステータスと規制当局によるインセンティブが、この分野の研究を後押ししています。小児臨床試験は世界規模で実施されるようになってきています。この世界化により、多様な患者集団へのアクセスが可能となり、患者募集に要する時間が短縮され、試験結果の一般化可能性が高まっています。政府機関、非営利団体、製薬会社からの資金援助が受けられるようになったことも、小児臨床試験の活動を後押ししています。これらの財源は、小児治療の研究を支援しています。

主な市場促進要因

希少疾患への関心の高まり

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の小児臨床試験市場展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • フェーズ別（第I相、第II相、第III相、第IV相）
  • 試験設計別（治療試験、観察試験）
  • 治療領域別（呼吸器疾患、感染症、がん、糖尿病、その他の治療領域）
  • 地域別
  • 企業別（2022年）
• 市場マップ

第6章 アジア太平洋の小児臨床試験市場展望

• 市場規模および予測
  • 金額別
• 市場シェアと予測
  • フェーズ別
  • 試験設計別
  • 治療設計別
  • 国別
• アジア太平洋：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第7章 欧州の小児臨床試験市場展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • フェーズ別
  • 試験設計別
  • 治療設計別
  • 国別
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第8章 北米の小児臨床試験市場展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • フェーズ別
  • 試験設計別
  • 治療設計別
  • 国別
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第9章 南米の小児臨床試験市場展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • フェーズ別
  • 試験設計別
  • 治療設計別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの小児臨床試験市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • フェーズ別
  • 試験設計別
  • 治療設計別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 製品上市
• 合併と買収

第13章 世界の小児臨床試験市場のSWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 PESTLE分析

第16章 競合情勢

• Bristol-Myers Squibb Company
• Charles River Laboratories International Inc.
• Covance Inc.
• GlaxoSmithKline plc
• ICON plc
• IQVIA Inc.
• Novartis AG
• Pfizer, Inc.
• Pharmaceutical Product Development, LLC
• Syneos Health Inc.
• Paidion Research, Inc.
• The Emmes Company, LLC

第17章 戦略的提言

第18章 調査会社・免責事項

Global Pediatric Clinical Trials Market has valued at USD 14.70 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 7.50% through 2028. Pediatric clinical trials are research studies conducted to evaluate the safety, efficacy, and dosing of medical treatments, interventions, drugs, devices, or therapies in pediatric populations, which includes infants, children, and adolescents. These trials are essential for improving the understanding and treatment of diseases and medical conditions that affect children. Conducting pediatric clinical trials requires a strong emphasis on ethical principles, including informed consent. Parents or legal guardians provide informed consent on behalf of pediatric participants. Researchers must ensure that the trial benefits outweigh potential risks for the child. Pediatric clinical trials measure specific endpoints and outcomes to evaluate the effects of treatments. These can include improvements in symptoms, disease progression, quality of life, and safety profiles.

The prevalence of pediatric diseases, including rare diseases and chronic conditions, has been on the rise. This drives the need for clinical trials to develop effective treatments for children. Advances in genomics and molecular biology have led to the development of targeted therapies for pediatric diseases. These innovative treatments require clinical trials to assess their safety and efficacy. Many pediatric clinical trials focus on rare diseases, which are often underserved by traditional drug development. Orphan drug status and incentives provided by regulators have driven research in this area. Pediatric clinical trials are increasingly conducted on a global scale. This globalization allows for access to diverse patient populations, reducing the time required for patient recruitment and enhancing the generalizability of trial results. The availability of funding from government agencies, nonprofit organizations, and pharmaceutical companies has boosted pediatric clinical trial activity. These financial resources support research into pediatric treatments.

Key Market Drivers

Growing Focus on Rare Diseases

Rare diseases, also known as orphan diseases, often lack approved treatments or have limited therapeutic options. Many of these diseases affect children, and pediatric patients with rare diseases face particularly challenging health conditions. Pediatric clinical trials are essential to develop treatments for these underserved populations. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), offer incentives to encourage the development of orphan drugs for rare diseases. These incentives include extended market exclusivity, tax credits, and waived application fees, which make pediatric clinical trials more attractive to pharmaceutical companies. Rare diseases often receive orphan drug designation, which grants special status to drugs intended to treat rare conditions. This designation can expedite the drug development process and increase funding opportunities for pediatric clinical trials. Patient advocacy groups for rare diseases play a crucial role in raising awareness, supporting research, and facilitating clinical trials. They often collaborate with researchers, clinicians, and industry partners to drive pediatric clinical trial initiatives.

Advances in genomics and personalized medicine have increased the understanding of the genetic basis of many rare diseases. This knowledge allows for the development of targeted therapies, making pediatric clinical trials more focused and promising. Rare diseases are, by definition, rare, and patients may be dispersed globally. Collaborative efforts among researchers, healthcare providers, and pharmaceutical companies on an international scale help pool resources and access diverse patient populations for clinical trials. Pediatric research networks, such as the Pediatric Trials Network (PTN) and the International Rare Diseases Research Consortium (IRDiRC), focus on rare diseases. They facilitate research, data sharing, and the conduct of pediatric clinical trials in the rare disease field. The orphan drug market, including treatments for rare pediatric diseases, can be financially attractive for pharmaceutical companies. Developing effective treatments for rare diseases can lead to market exclusivity and premium pricing. Advances in biomedical research, including gene therapy, gene editing, and cell-based therapies, have opened new avenues for treating rare diseases. These cutting-edge approaches often require pediatric clinical trials to assess safety and efficacy. Successful pediatric clinical trials for rare diseases can have a profound and lasting impact on patients' lives. They offer the potential to improve or even save the lives of children who would otherwise have limited treatment options. This factor will help in the development of Global Pediatric Clinical Trials Market.

Advancements in Precision Medicine

The mapping of an individual's genome has become more accessible and cost-effective. Next-generation sequencing (NGS) technologies have revolutionized genomics, enabling the sequencing of entire genomes, exomes, and specific gene panels. This information is used to identify genetic mutations, variations, and susceptibilities to specific diseases. Pharmacogenomics studies how an individual's genetic makeup affects their response to drugs. By understanding genetic variations, healthcare providers can prescribe medications that are more likely to be effective and have fewer adverse effects for a particular patient. Precision oncology utilizes genomic profiling of tumors to identify specific genetic alterations that drive cancer growth. Targeted therapies and immunotherapies are designed to attack cancer cells based on their molecular characteristics, leading to more effective and less toxic treatments. Liquid biopsy techniques allow for the non-invasive detection of cancer and other diseases by analyzing genetic material (e.g., DNA, RNA) in bodily fluids like blood. This approach enables early cancer detection, monitoring treatment responses, and tracking disease progression. Single-cell sequencing technologies enable the study of individual cells within complex tissues. This is invaluable for understanding cell heterogeneity in diseases, such as cancer, and for developing personalized treatments. Epigenetics focuses on modifications to DNA that do not change the underlying genetic code but affect gene expression. Understanding epigenetic changes can provide insights into disease mechanisms and potential therapeutic targets.

AI and machine learning algorithms can analyze large-scale genomic and clinical data to identify patterns and predict disease risk, progression, and treatment responses. These tools aid in personalized treatment recommendations. Immunogenomics combines genomics and immunology to understand how an individual's immune system interacts with diseases. It is essential in developing personalized immunotherapies, such as CAR-T cell therapy for cancer. Genomic sequencing has improved the diagnosis of rare genetic diseases, many of which affect children. Identifying the genetic cause of these conditions can lead to more accurate diagnoses and potential treatments. Patients can contribute to their own precision medicine by providing data through wearable devices and mobile apps. This real-time data can be integrated with genetic and clinical information to personalize healthcare. Large-scale genomic studies help identify genetic risk factors for common diseases like heart disease, diabetes, and Alzheimer's. This knowledge can inform preventive measures and early interventions. As precision medicine advances, ethical considerations surrounding privacy, consent, and data sharing become increasingly important. Regulatory agencies are developing guidelines to ensure the responsible use of genomic and personalized data. This factor will pace up the demand of Global Pediatric Clinical Trials Market.

Increasing Pediatric Health Issues

Pediatric health issues, including chronic conditions, rare diseases, and developmental disorders, are on the rise globally. As the pediatric population grows, so does the number of children affected by these conditions, necessitating clinical research to develop effective treatments. Many pediatric diseases and conditions have limited or no approved treatments. Pediatric patients often face unmet medical needs, and clinical trials are crucial for developing new therapies that can improve their health and quality of life. Advances in genomics have increased our understanding of genetic and congenital disorders in children. This knowledge has opened new avenues for developing targeted therapies, personalized medicine, and gene-based treatments, all of which require clinical trials. Cancer is one of the leading causes of death among children. Pediatric oncology clinical trials are critical for developing more effective and less toxic treatments for childhood cancers.

Emerging infectious diseases and the ongoing threat of epidemics and pandemics, such as COVID-19, highlight the need for clinical trials to test vaccines and treatments for pediatric populations. Neurodevelopmental disorders, such as autism spectrum disorders and attention-deficit/hyperactivity disorder (ADHD), are increasingly prevalent. Clinical trials aim to develop interventions that can improve the lives of children with these conditions. Premature birth and neonatal health issues are significant concerns. Clinical trials in neonatology focus on improving outcomes for premature and critically ill newborns. The rising incidence of childhood obesity and related metabolic disorders necessitates research into interventions and treatments. Pediatric clinical trials play a role in addressing these health issues. Mental health issues in children, including anxiety, depression, and behavioral disorders, are receiving greater attention. Clinical trials aim to identify effective therapies and interventions. Various global health organizations and initiatives prioritize improving pediatric healthcare and access to essential medications. They support and fund clinical trials as part of their mission to address pediatric health challenges. This factor will accelerate the demand of Global Pediatric Clinical Trials Market.

Key Market Challenges

Diversity and Representation

Clinical trial results need to be applicable to the entire population, including various demographic groups. Lack of diversity can lead to biased or incomplete findings that may not accurately reflect how a treatment will work in real-world settings, especially for underrepresented populations. Pediatric clinical trials that do not include diverse populations can perpetuate health disparities. Certain ethnic and racial groups may be disproportionately affected by certain diseases, and they should have the opportunity to benefit from advances in pediatric medicine. Genetic, physiological, and environmental factors can influence how treatments affect individuals. It's essential to understand how a drug or intervention works in diverse populations, including different age groups, genders, ethnicities, and socioeconomic backgrounds. Pediatric clinical trials require informed consent from parents or guardians. Ensuring that these caregivers have access to understandable information and that they represent diverse backgrounds is an ethical imperative. Regulatory agencies, such as the FDA and EMA, encourage or require the inclusion of diverse populations in clinical trials. Failure to meet these requirements can delay regulatory approvals. Engaging with diverse communities is essential for building trust and encouraging participation in clinical trials. Community partnerships can help identify barriers to participation and develop strategies to overcome them. Cultural factors can influence healthcare decision-making. Clinical trial protocols and recruitment strategies should be culturally sensitive to engage a broad range of participants.

Parental Concerns and Reluctance

Parents are naturally concerned about the safety of their children. They may worry about potential risks and adverse effects associated with the investigational treatments or interventions being tested in the trial. Insufficient information or understanding about the trial, its purpose, procedures, and potential benefits can lead to parental reluctance. Effective communication and providing clear, comprehensible information are critical. Some parents may perceive clinical trials as experimental and fear that their child will be treated like a "guinea pig." Addressing these misconceptions through education is essential. Parents may have ethical concerns, such as whether it is morally acceptable to enroll their child in a clinical trial, especially if they perceive a potential conflict between the child's well-being and the trial's goals. In randomized controlled trials, some children may receive a placebo or standard treatment instead of investigational therapy. Parents may be reluctant to enroll their child if they believe the child will receive a placebo. Participation in clinical trials often involves additional time, travel, and commitments. Parents may face logistical challenges, such as scheduling conflicts or the need for frequent clinic visits. Trust in healthcare providers and the research institution is crucial for parental willingness to enroll their child in a clinical trial. Any perceived lack of trustworthiness can deter participation. Language barriers and cultural differences can make it difficult for parents to fully understand the trial's details and make informed decisions. Culturally sensitive communication is essential.

Key Market Trends

Increasing Emphasis on Pediatric Drug Development

The pediatric drug market represents a significant opportunity for pharmaceutical companies. Developing medications specifically for children can lead to market exclusivity and premium pricing, incentivizing investment in pediatric drug development. Advances in pediatric healthcare and medicine have expanded the potential for drug development. Innovative therapies, precision medicine approaches, and genetic-based treatments offer new avenues for addressing pediatric diseases. Pediatric research networks and collaborations, such as the Pediatric Trials Network (PTN) and the International Neonatal Consortium (INC), facilitate pediatric drug development by bringing together expertise, resources, and patient populations. Patient advocacy groups and organizations dedicated to pediatric health play a crucial role in raising awareness about the importance of pediatric clinical trials and advocating for research in pediatric drug development. Various global health organizations and initiatives prioritize improving pediatric healthcare and access to essential medications, further driving the emphasis on pediatric drug development.

Segmental Insights

Phase Insights

In 2022, the Global Pediatric Clinical Trials Market dominated by phase II trials segment and is predicted to continue expanding over the coming years. Phase II clinical trials are a critical stage in drug development where the safety and efficacy of a potential treatment are evaluated in a relatively small but diverse group of patients. In the context of pediatric trials, it is crucial to thoroughly assess the safety and effectiveness of investigational drugs in children before advancing to larger, more complex trials. Pediatric patients, especially infants and young children, are vulnerable, and their bodies may respond differently to medications compared to adults. Conducting Phase II trials allows researchers to gather essential data on dosage, safety profiles, and potential side effects in the pediatric population while minimizing exposure to potential risks. Phase II trials help determine the appropriate dosage of a drug for pediatric patients. This is crucial because children often require different dosages than adults due to differences in metabolism, body weight, and other factors.

Study Design Insights

In 2022, the Global Pediatric Clinical Trials Market largest share was held by Treatment studies segment and is predicted to continue expanding over the coming years. Pediatric clinical trials in the Treatment studies segment are primarily focused on developing and testing treatments for various pediatric diseases and conditions. There is a significant clinical necessity to find effective therapies for children, as many medical conditions affect them differently than adults. Many childhood diseases and conditions, including congenital disorders, genetic diseases, rare diseases, and pediatric cancers, require specific treatments. The prevalence of such conditions necessitates extensive research to find and validate effective treatment options. Pediatric patients often face unmet medical needs, where there may be limited or no approved treatments available. This creates a strong incentive for pharmaceutical companies and researchers to invest in clinical trials to address these gaps in pediatric care.

Therapeutic Areas Insights

In 2022, the Global Pediatric Clinical Trials Market largest share was held by oncology segment in the forecast period and is predicted to continue expanding over the coming years. Pediatric oncology trials are prominent because cancer is one of the leading causes of death among children worldwide. Childhood cancers, although relatively rare compared to adult cancers, still affect a significant number of pediatric patients. This prevalence necessitates extensive clinical research to develop more effective treatments. Despite advances in pediatric oncology, there are still many unmet medical needs. Many types of childhood cancers have limited treatment options, and there is a pressing need for innovative therapies with fewer side effects. Advances in genomics and molecular biology have led to the development of targeted therapies for pediatric cancers. These therapies are often tested in clinical trials to determine their safety and efficacy, further driving research in paediatric oncology.

Regional Insights

The North America region dominates the Global Pediatric Clinical Trials Market in 2022. North America, especially the United States, is home to a substantial pharmaceutical and biotechnology industry. Many major pharmaceutical companies and research institutions are based in the United States, which leads to a concentration of resources and expertise in conducting clinical trials, including pediatric trials. The United States has a well-established regulatory framework, primarily governed by the Food and Drug Administration (FDA), for conducting clinical trials. The FDA has specific guidelines and incentives to encourage pediatric drug development, such as the Pediatric Research Equity Act (PREA) and the Best Pharmaceuticals for Children Act (BPCA). North America boasts a strong and well-developed healthcare infrastructure, which includes top-tier hospitals, research centers, and clinical trial facilities. This infrastructure is vital for conducting pediatric clinical trials.

Key Market Players

• Bristol-Myers Squibb Company

• Charles River Laboratories International Inc.

• Covance Inc.

• GlaxoSmithKline plc

• ICON plc

• IQVIA Inc.

• Novartis AG

• Pfizer, Inc.

• Pharmaceutical Product Development, LLC

• Syneos Health Inc.

• Paidion Research, Inc.

• The Emmes Company, LLC

Report Scope:

In this report, the Global Pediatric Clinical Trials Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pediatric Clinical Trials Market, By Phase:

• Phase I
• Phase II
• Phase III
• Phase IV

Pediatric Clinical Trials Market, By Study Design:

• Treatment Studies
• Observational Studies

Pediatric Clinical Trials Market, By Therapeutic Area:

• Respiratory Disease
• Infectious Diseases Oncology
• Diabetes
• Other Therapeutic Areas

Global Pediatric Clinical Trials Market, By region:

• North America
• United States
• Canada
• Mexico
• Asia-Pacific
• China
• India
• South Korea
• Australia
• Japan
• Europe
• Germany
• France
• United Kingdom
• Spain
• Italy
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Pediatric Clinical Trials Market.

Available Customizations:

• Global Pediatric Clinical Trials Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pediatric Clinical Trials Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Phase (Phase I, Phase II, Phase III, and Phase IV)
  • 5.2.2. By Study Design (Treatment Studies and Observational Studies)
  • 5.2.3. By Therapeutic Area (Respiratory Diseases, Infectious Diseases, Oncology, Diabetes, and Other Therapeutic Areas)
  • 5.2.4. By Region
  • 5.2.5. By Company (2022)
• 5.3. Market Map

6. Asia Pacific Pediatric Clinical Trials Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Phase
  • 6.2.2. By Study Design
  • 6.2.3. By Therapeutic Design
  • 6.2.4. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Pediatric Clinical Trials Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Phase
      • 6.3.1.2.2. By Study Design
      • 6.3.1.2.3. By Therapeutic Design
  • 6.3.2. India Pediatric Clinical Trials Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Phase
      • 6.3.2.2.2. By Study Design
      • 6.3.2.2.3. By Therapeutic Design
  • 6.3.3. Australia Pediatric Clinical Trials Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Phase
      • 6.3.3.2.2. By Study Design
      • 6.3.3.2.3. By Therapeutic Design
  • 6.3.4. Japan Pediatric Clinical Trials Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Phase
      • 6.3.4.2.2. By Study Design
      • 6.3.4.2.3. By Therapeutic Design
  • 6.3.5. South Korea Pediatric Clinical Trials Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Phase
      • 6.3.5.2.2. By Study Design
      • 6.3.5.2.3. By Therapeutic Design

7. Europe Pediatric Clinical Trials Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Phase
  • 7.2.2. By Study Design
  • 7.2.3. By Therapeutic Design
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Pediatric Clinical Trials Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Phase
      • 7.3.1.2.2. By Study Design
      • 7.3.1.2.3. By Therapeutic Design
  • 7.3.2. Germany Pediatric Clinical Trials Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Phase
      • 7.3.2.2.2. By Study Design
      • 7.3.2.2.3. By Therapeutic Design
  • 7.3.3. Spain Pediatric Clinical Trials Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Phase
      • 7.3.3.2.2. By Study Design
      • 7.3.3.2.3. By Therapeutic Design
  • 7.3.4. Italy Pediatric Clinical Trials Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Phase
      • 7.3.4.2.2. By Study Design
      • 7.3.4.2.3. By Therapeutic Design
  • 7.3.5. United Kingdom Pediatric Clinical Trials Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Phase
      • 7.3.5.2.2. By Study Design
      • 7.3.5.2.3. By Therapeutic Design

8. North America Pediatric Clinical Trials Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Phase
  • 8.2.2. By Study Design
  • 8.2.3. By Therapeutic Design
  • 8.2.4. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Pediatric Clinical Trials Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Phase
      • 8.3.1.2.2. By Study Design
      • 8.3.1.2.3. By Therapeutic Design
  • 8.3.2. Mexico Pediatric Clinical Trials Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Phase
      • 8.3.2.2.2. By Study Design
      • 8.3.2.2.3. By Therapeutic Design
  • 8.3.3. Canada Pediatric Clinical Trials Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Phase
      • 8.3.3.2.2. By Study Design
      • 8.3.3.2.3. By Therapeutic Design

9. South America Pediatric Clinical Trials Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Phase
  • 9.2.2. By Study Design
  • 9.2.3. By Therapeutic Design
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Pediatric Clinical Trials Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Phase
      • 9.3.1.2.2. By Study Design
      • 9.3.1.2.3. By Therapeutic Design
  • 9.3.2. Argentina Pediatric Clinical Trials Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Phase
      • 9.3.2.2.2. By Study Design
      • 9.3.2.2.3. By Therapeutic Design
  • 9.3.3. Colombia Pediatric Clinical Trials Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Phase
      • 9.3.3.2.2. By Study Design
      • 9.3.3.2.3. By Therapeutic Design

10. Middle East and Africa Pediatric Clinical Trials Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Phase
  • 10.2.2. By Study Design
  • 10.2.3. By Therapeutic Design
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Pediatric Clinical Trials Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Phase
      • 10.3.1.2.2. By Study Design
      • 10.3.1.2.3. By Therapeutic Design
  • 10.3.2. Saudi Arabia Pediatric Clinical Trials Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Phase
      • 10.3.2.2.2. By Study Design
      • 10.3.2.2.3. By Therapeutic Design
  • 10.3.3. UAE Pediatric Clinical Trials Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Phase
      • 10.3.3.2.2. By Study Design
      • 10.3.3.2.3. By Therapeutic Design

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Pediatric Clinical Trials Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Bristol-Myers Squibb Company
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. SWOT Analysis
• 16.2. Charles River Laboratories International Inc.
  • 16.2.1. Business Overview
  • 16.2.2. Company Snapshot
  • 16.2.3. Products & Services
  • 16.2.4. Financials (In case of listed companies)
  • 16.2.5. Recent Developments
  • 16.2.6. SWOT Analysis
• 16.3. Covance Inc.
  • 16.3.1. Business Overview
  • 16.3.2. Company Snapshot
  • 16.3.3. Products & Services
  • 16.3.4. Financials (In case of listed companies)
  • 16.3.5. Recent Developments
  • 16.3.6. SWOT Analysis
• 16.4. GlaxoSmithKline plc
  • 16.4.1. Business Overview
  • 16.4.2. Company Snapshot
  • 16.4.3. Products & Services
  • 16.4.4. Financials (In case of listed companies)
  • 16.4.5. Recent Developments
  • 16.4.6. SWOT Analysis
• 16.5. ICON plc
  • 16.5.1. Business Overview
  • 16.5.2. Company Snapshot
  • 16.5.3. Products & Services
  • 16.5.4. Financials (In case of listed companies)
  • 16.5.5. Recent Developments
  • 16.5.6. SWOT Analysis
• 16.6. IQVIA Inc.
  • 16.6.1. Business Overview
  • 16.6.2. Company Snapshot
  • 16.6.3. Products & Services
  • 16.6.4. Financials (In case of listed companies)
  • 16.6.5. Recent Developments
  • 16.6.6. SWOT Analysis
• 16.7. Novartis AG
  • 16.7.1. Business Overview
  • 16.7.2. Company Snapshot
  • 16.7.3. Products & Services
  • 16.7.4. Financials (In case of listed companies)
  • 16.7.5. Recent Developments
  • 16.7.6. SWOT Analysis
• 16.8. Pfizer, Inc.
  • 16.8.1. Business Overview
  • 16.8.2. Company Snapshot
  • 16.8.3. Products & Services
  • 16.8.4. Financials (In case of listed companies)
  • 16.8.5. Recent Developments
  • 16.8.6. SWOT Analysis
• 16.9. Pharmaceutical Product Development, LLC
  • 16.9.1. Business Overview
  • 16.9.2. Company Snapshot
  • 16.9.3. Products & Services
  • 16.9.4. Financials (In case of listed companies)
  • 16.9.5. Recent Developments
  • 16.9.6. SWOT Analysis
• 16.10. Syneos Health Inc.
  • 16.10.1. Business Overview
  • 16.10.2. Company Snapshot
  • 16.10.3. Products & Services
  • 16.10.4. Financials (In case of listed companies)
  • 16.10.5. Recent Developments
  • 16.10.6. SWOT Analysis
• 16.11. Paidion Research, Inc.
  • 16.11.1. Business Overview
  • 16.11.2. Company Snapshot
  • 16.11.3. Products & Services
  • 16.11.4. Financials (In case of listed companies)
  • 16.11.5. Recent Developments
  • 16.11.6. SWOT Analysis
• 16.12. The Emmes Company, LLC
  • 16.12.1. Business Overview
  • 16.12.2. Company Snapshot
  • 16.12.3. Products & Services
  • 16.12.4. Financials (In case of listed companies)
  • 16.12.5. Recent Developments
  • 16.12.6. SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer